Search clinical trials for: EGFR Mutation

Total 4261 results

Fujian Cancer Hospital

Unknown

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Chemotherapy Effect | NSCLC Stage IV

China
Baohui Han

Completed

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. (ML25444)

Non Small Cell Lung Cancer

China
Association des Gastroentérologues Oncologues
Pitié-Salpêtrière Hospital; Hôpital Européen George Pompidou, APHP, Paris,... and other collaborators

Unknown

RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) (RASINTRO)

Metastatic Colorectal Cancer
Hoffmann-La Roche

Completed

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations

Non-Squamous Non-Small Cell Lung Cancer

Spain
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE)

NSCLC

China
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
AstraZeneca

Completed

Asia Pacific and Russia Diagnostic Study for EGFR Testing (IGNITE)

EGFR Mutation Status in aNSCLC Patients

Korea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
Sichuan Cancer Hospital and Research Institute

Unknown

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Lung Cancer Stage IV
Spanish Lung Cancer Group

Completed

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone (GOAL)

Non Small Cell Lung Cancer

Spain
Hoffmann-La Roche

Completed

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations (BIOTEC)

Carcinoma，Non-Small-Cell Lung

Romania
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada
AstraZeneca

Completed

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Guangdong Provincial People's Hospital

Unknown

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC (TREND)

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
Peking University Cancer Hospital & Institute

Unknown

Blood Detection of EGFR Mutation For Iressa Treatment (Benefit)

Lung Adenocarcinoma

China
Samsung Medical Center

Unknown

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Jinming Yu
Roche Pharma AG

Unknown

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 (RECEL)

Non-small Cell Lung Cancer

China
Symphogen A/S

Withdrawn

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Metastatic Colorectal Cancer
Zaiwen Fan

Unknown

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Advanced Cancer | Lung Cancer, Nonsmall Cell
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Yonsei University

Withdrawn

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

NSCLC
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Nonsmall Cell Lung Cancer | EGFR Gene Mutation
National Taiwan University Hospital

Unknown

Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC

Lung Cancer

Taiwan
University Hospital, Essen

Completed

EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA (EGFRdelEx19)

Lung Adenocarcinoma Metastatic
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
Cancer Institute and Hospital, Chinese Academy...

Unknown

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Non-Squamous Non-Small Cell Lung Cancer

Germany
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
First People's Hospital of Hangzhou

Unknown

ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

Non-small Cell Lung Cancer Stage III | Adenocarcinoma of Lung | Non-Small-Cell Lung Cancer Metastatic | EGFR Wildtype

China
Tianjin Medical University Cancer Institute and...
Roche Pharma AG

Unknown

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Non-small Cell Lung Cancer Stage III

China
Caicun Zhou

Unknown

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Massachusetts General Hospital
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana-Farber...

Completed

Detecting EGFR T790M Mutations From Circulating Tumor Cells

Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
Boehringer Ingelheim

Completed

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Carcinoma, Non-Small-Cell Lung

United States, Taiwan
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery...

Unknown

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Non-Small-Cell Lung Cancer
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
Hoffmann-La Roche

Completed

A Study of Prevalence of EGFR Mutations in Participants With NSCLC

Non-Small Cell Lung Cancer

Jordan
Zhejiang Cancer Hospital

Unknown

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Non-small Cell Lung Cancer | Aquired Resistance | EGFR TKIs

China
Peking Union Medical College Hospital

Unknown

A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis

Non-small Cell Lung Cancer | Leptomeningeal Metastasis

China
First People's Hospital of Hangzhou

Unknown

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Lung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
Henan Provincial People's Hospital

Unknown

Conmana Combined With Thalidomide to Treat NSCLC

NSCLC

China
Baohui Han

Completed

Combination of Chemotherapy and Gefitinib as First-line Treatment

Non-Small-Cell Lung Cancer

China

Search clinical trials for: EGFR Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations